Neoadjuvant Therapy Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Contrast-enhanced Spectral Mammography (CESM) Early Quantitative Evaluation of Tumoral Response and Pathologic Complete Response Prediction for Localized Breast Cancer Treated by Neoadjuvant Chemotherapy
Conditions: Breast Cancer Interventions: Diagnostic Test: Diagnostic test Sponsors: Hospices Civils de Lyon Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 7, 2024 Category: Research Source Type: clinical trials

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations
Conditions: Non Small Cell Lung Cancer Interventions: Drug: Adebrelimab; Drug: paclitaxel for injection (albumin bound); Drug: Cisplatin or Carboplatin Sponsors: Liaoning Tumor Hospital& Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 7, 2024 Category: Research Source Type: clinical trials

Biomarker Driven Patient Selection Neoadjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
Conditions: Melanoma Stage III; Melanoma Stage IV; Advanced Melanoma; Melanoma Interventions: Drug: Nivolumab; Drug: Nivolumab + Relatlimab; Drug: Ipilimumab Sponsors: H. Lee Moffitt Cancer Center and Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2024 Category: Research Source Type: clinical trials

Bladder Cancer and Neoadjuvant Chemotherapy Efficiency Before Cystectomy
Conditions: Bladder Cancer; Genomic Instability Interventions: Combination Product: neoadjuvant chemotherapy with cisplatine Sponsors: University Hospital, Rouen; Institut Curie Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2024 Category: Research Source Type: clinical trials

Relation Between Tumor-draining Lymph Nodes Metastasis Pattern and Non-small Cell Lung Cancer Neoadjuvant Immunotherapy Effectiveness
Conditions: Lung Cancer Interventions: Drug: Immunotherapy Sponsors: Sun Yat-sen University; Jiangmen Central Hospital; Henan Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials

Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy
Conditions: Malignant Neoplasm of Bladder; Muscle Invasive Bladder Carcinoma Interventions: Drug: Neoadjuvant Chemotherapy; Procedure: Partial cystectomy with Extended pelvic lymph node dissection; Drug: Adjuvant systemic therapy Sponsors: Case Comprehensive Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials

Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer
Conditions: Cervical Cancer; Neoadjuvant Chemoimmunotherapy; Radical Hysterectomy; Fertility Preservation Interventions: Drug: Cadonilimab; Drug: Paclitaxel-albumin; Drug: Cisplatin; Procedure: Extrafascial hysterectomy Sponsors: Tongji Hospital; The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial); Women Hospital, School of Medicine, Zhejiang University; Southwest Hospital, China; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Sichuan Cancer Hospital and Research Institute; Qilu Hospital of Shandong University; Beijing Friendship Hospital; Tianjin Medical University; Wes...
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
Conditions: Cervical Cancer; Locally Advanced Cervical Cancer; Concurrent Chemoradiotherapy; Neoadjuvant Chemoimmunotherapy Interventions: Drug: Camrelizumab; Drug: Cisplatin; Drug: Nab paclitaxel; Procedure: Radical surgery; Radiation: external beam radiation therapy (EBRT) + brachytherapy; Drug: Cisplatin Sponsors: Tongji Hospital; Southwest Hospital, China; Women Hospital, School of Medicine, Zhejiang University; Anhui Provincial Cancer Hospital; Sichuan Cancer Hospital and Research Institute; Qilu Hospital of Shandong University; Beijing Friendship Hospital; Tianjin Medical University General Hospital; West China Secon...
Source: ClinicalTrials.gov - March 1, 2024 Category: Research Source Type: clinical trials

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer
Conditions: Cervical Cancer; Neoadjuvant Chemoimmunotherapy; Fertility Preservation Interventions: Drug: Camrelizumab; Drug: Cisplatin; Drug: Nab paclitaxel; Procedure: biopsy Sponsors: Tongji Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Women Hospital, School of Medicine, Zhejiang University; Third Military Medical University; Beijing Friendship Hospital; Sichuan Cancer Hospital and Research Institute; Tianjin Medical University; West China Second University Hospital; Xiangya Hospital of Central South University; Qilu Hospital of Shandong University; Gansu Cancer Hospital; Zhejiang Cancer Hospital; S...
Source: ClinicalTrials.gov - March 1, 2024 Category: Research Source Type: clinical trials

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
Conditions: Cervical Cancer; Locally Advanced Cervical Cancer; PD-L1 Negative; Neoadjuvant Chemoimmunotherapy Interventions: Drug: Camrelizumab; Drug: Paclitaxel-albumin; Drug: Cisplatin; Procedure: radical surgery Sponsors: Tongji Hospital; Southwest Hospital, China; Women Hospital, School of Medicine, Zhejiang University; Anhui Provincial Cancer Hospital; Sichuan Cancer Hospital and Research Institute; Gansu Provincial Maternal and Child Health Care Hospital; Beijing Friendship Hospital; Tianjin Medical University General Hospital; Xiangya Hospital of Central South University; West China Second University Hospital; Sun Y...
Source: ClinicalTrials.gov - March 1, 2024 Category: Research Source Type: clinical trials

Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma
Conditions: Cutaneous Squamous Cell Carcinoma Interventions: Drug: Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination Sponsors: Melanoma Institute Australia; Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 1, 2024 Category: Research Source Type: clinical trials

The Feasibility of Dynamic Liquid Biopsy Monitoring During Neoadjuvant Treatment for EGFR-mutated NSCLC
Conditions: EGF-R Positive Non-Small Cell Lung Cancer Interventions: Other: ctDNA monitoring Sponsors: Zhejiang University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 1, 2024 Category: Research Source Type: clinical trials

Deep Learning Model Predicts Pathological Complete Response of Lung Cancer Following Neoadjuvant Immunochemotherapy
Conditions: Deep Learning Model; Pathological Complete Response; Non-small Cell Lung Cancer; Neoadjuvant Chemoimmunotherapy Interventions: Diagnostic Test: No interventions Sponsors: Wuhan Union Hospital, China Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Conditions: Colorectal Cancer; Liver Metastases Interventions: Drug: Oxaliplatin; Drug: Fluorouracil; Drug: Serplulimab; Drug: Bevacizumab Sponsors: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials

Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery
Conditions: Breast Cancer; Triple Negative Breast Cancer; HER2-positive Breast Cancer; Neoadjuvant Chemotherapy Interventions: Procedure: Omission of surgical treatment Sponsors: European Institute of Oncology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials